Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Inhibrx Biosciences, Inc. (INBX : NSDQ)

• Company Description    Inhibrx Inc. is a clinical-stage biopharmaceutical company. It focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx Inc. is based in SAN DIEGO. Number of Employees: 110

• Price / Volume Information    Yesterday's Closing Price: $101.32 Daily Weekly Monthly 20 Day Moving Average: 572,214 shares Shares Outstanding: 14.67 (millions) Market Capitalization: $1,486.47 (millions) Beta: 3.88 52 Week High: $155.29 52 Week Low: $12.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.52% -19.64% 12 Week 31.19% 21.28% Year To Date 28.25% 28.68%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11025 N. TORREY PINES ROAD SUITE 140 - LA JOLLA,CA 92037 USA ph: 858-795-4220 fax: - ir@inhibrx.com https://inhibrx.com

• General Corporate Information    Officers Mark P. Lappe - Chief Executive Officer and Chairman Kelly D. Deck - Chief Financial Officer Jon Faiz Kayyem - Director Douglas G. Forsyth - Director Kimberly Manhard - Director Peer Information Inhibrx Biosciences, Inc. (CORR.) Inhibrx Biosciences, Inc. (RSPI) Inhibrx Biosciences, Inc. (CGXP) Inhibrx Biosciences, Inc. (BGEN) Inhibrx Biosciences, Inc. (GTBP) Inhibrx Biosciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45720N103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 14.67 Most Recent Split Date: (:1) Beta: 3.88 Market Capitalization: $1,486.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.50 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-10.15 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 23.21% vs. Previous Quarter: -1.90% Sales Growth vs. Year Ago Period: 1,200.00% vs. Previous Quarter: -% ROE 03/31/26 - -563.90 12/31/25 - -269.56 09/30/25 - -186.06 ROA 03/31/26 - -72.32 12/31/25 - -71.94 09/30/25 - -76.30 Current Ratio 03/31/26 - 6.46 12/31/25 - 3.93 09/30/25 - 4.49 Quick Ratio 03/31/26 - 6.46 12/31/25 - 3.93 09/30/25 - 4.49 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - -10,014.08 12/31/25 - -10,773.31 09/30/25 - -11,077.43 Book Value 03/31/26 - -1.43 12/31/25 - 0.55 09/30/25 - 2.54 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - 12.58 09/30/25 - 2.71 Debt-to-Capital 03/31/26 - - 12/31/25 - 92.64 09/30/25 - 73.07

Powered by Zacks Investment Research ©